Ultragenyx Pharmaceutical Inc Analyst and Investor Day Transcript
Good morning, everyone. I am Emil Kakkis, in case you don't know, I'm sure most of you do know. I'm the CEO of Ultragenyx, and we're here to talk today about the progress we've been making as a company, both in the commercial products, in our gene therapy and in our early-stage program, to give you a deeper dive into what we're doing to change the lives of rare disease patients.
This is our legal warning and if you look at our SEC filings for the risks of investing in Ultragenyx.
The agenda today is really divided into 3 main sections. I'll do a brief overview right now, but there will be a commercial and late-stage pipeline to talk about Crysvita primarily, but also a little bit about the FAOD program.
We'll talk then in the gene therapy section, we'll hear about the current gene therapy programs. And we have some experts with us today to talk as well about those diseases, which will include a little bit of a discussion of Wilson, which is our next clinical gene therapy program.
In the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
